Agenda

Public Workshop: Emerging Tick-Borne Diseases & Blood Safety

April 6, 2017
Ruth Kirschstein Auditorium, Natcher Building, NIH Campus, Bethesda MD

Sponsors:
Center for Biologics Evaluation and Research, FDA
American Association of Blood
America’s Blood Centers
National Heart, Lung, and Blood Institute, NIH
U.S. Department of Defense
U.S. Department of Health and Human Services

Morning Session:

7:30 AM Registration Opens

8:30 AM Welcome Address
Peter W. Marks, MD, PhD - FDA

8:40 AM Announcements, Objectives, and FDA Perspective on Emerging Tick-Borne Diseases
David A. Leiby, PhD - FDA

8:55 AM Plenary Presentation on Tick-Borne Diseases
Peter J. Krause, MD – Yale University

Session 1: Biology, Epidemiology and Clinical Burden of Human Granulocytic Anaplasmosis (HGA)

9:30 AM Anaplasma phagocytophilum, Etiologic Agent of Human Granulocytic Anaplasmosis
Cara Cherry, DVM, MPH - CDC

9:55 AM Clinical Aspects of Human Granulocytic Anaplasmosis
J. Stephen Dumler, MD - USUHS

10:20 AM Coffee Break – Sponsored by AABB
Session 2: Biology, Epidemiology and Clinic Burden of Other Emerging Tick-Borne Agents

10:50 AM Other Emerging Tick-Borne Agents
   Sam R. Telford III, PhD – Tufts University

11:20 AM One State’s Perspective on Burgeoning Tick-borne Diseases
   Alfred DeMaria, Jr., MD – Massachusetts Department of Health

11:50 AM Roundtable Discussion I
   Morning Speakers; Bryan R. Spencer, MPH – American Red Cross; and Hira L. Nakhasi, PhD - FDA

12:20 PM Lunch

Afternoon Session:

Session 3: Transfusion Transmission

1:20 PM Transmission Risks Posed by Emergent Agents
   David A. Leiby, PhD - FDA

1:45 PM Incidence of Transfusion Transmission (HGA and Other Agents)
   Susan L. Stramer, PhD – American Red Cross

2:10 PM Coffee Break – Sponsored by America’s Blood Centers

Session 4: Mitigation Efforts

2:40 PM Mitigating Infectious Risks of Blood Transfusion
   Louis M. Katz, MD – America’s Blood Centers

3:10 PM Conceptual Framework for Test Development
   Raymond P. Goodrich, PhD – Colorado State University

3:40 PM Risk Based Decision Making: The ABO Approach
   Judie Leach Bennett, LLM – Canadian Blood Services

4:10 PM Roundtable Discussion II
   Afternoon Speakers; CAPT Roland L. Fahie - DoD; Roger Y. Dodd, PhD – American Red Cross; and Jay S. Epstein, MD - FDA

5:00 PM Summary & Wrap-up
   David A. Leiby, PhD - FDA

5:15 PM Adjourn